← stocks-llm New chat

ENANTA PHARMACEUTICALS INC (ENTA) — insider trading

Health Care · NASDAQ

ENANTA PHARMACEUTICALS INC (ENTA) has 24 reported SEC Form 4 insider transactions in our data (latest 2026-03-11).

Recent Form 4 transactions

DateInsiderRoleTypeSharesPriceValueFiling
2026-03-11 CARTER BRUCE L A Director Grant / award / vesting (derivative) 20,000 $0.00 $0 Form 4
2026-03-11 FOLETTA MARK G Director Grant / award / vesting (derivative) 20,000 $0.00 $0 Form 4
2026-03-11 Hata Yujiro S Director Grant / award / vesting (derivative) 20,000 $0.00 $0 Form 4
2026-03-11 Peterson Kristine Director Grant / award / vesting (derivative) 20,000 $0.00 $0 Form 4
2026-03-11 Russell Lesley Director Grant / award / vesting (derivative) 20,000 $0.00 $0 Form 4
2026-03-11 Vance Terry Director Grant / award / vesting (derivative) 20,000 $0.00 $0 Form 4
2026-02-12 Luly Jay R. Director, Officer (President and CEO) Shares withheld for taxes / exercise cost 6,155 $14.25 $87.7K Form 4
2026-02-12 Luly Jay R. Director, Officer (President and CEO) Grant / award / vesting 15,200 $0.00 $0 Form 4
2026-02-12 Luly Jay R. Director, Officer (President and CEO) Grant / award / vesting 4,800 $0.00 $0 Form 4
2026-02-12 Or Yat Sun Officer (Chief Scientific Officer) Shares withheld for taxes / exercise cost 3,413 $14.25 $48.6K Form 4
2026-02-12 Or Yat Sun Officer (Chief Scientific Officer) Grant / award / vesting 5,225 $0.00 $0 Form 4
2026-02-12 Or Yat Sun Officer (Chief Scientific Officer) Grant / award / vesting 1,650 $0.00 $0 Form 4
2026-02-12 Rottinghaus Scott T. Officer (Chief Medical Officer) Shares withheld for taxes / exercise cost 3,413 $14.25 $48.6K Form 4
2026-02-12 Rottinghaus Scott T. Officer (Chief Medical Officer) Grant / award / vesting 5,225 $0.00 $0 Form 4
2026-02-12 Rottinghaus Scott T. Officer (Chief Medical Officer) Grant / award / vesting 1,650 $0.00 $0 Form 4
2026-02-12 Kieffer Tara Lynn Officer (Chief Product Strategy Officer) Shares withheld for taxes / exercise cost 3,257 $14.25 $46.4K Form 4
2026-02-12 Kieffer Tara Lynn Officer (Chief Product Strategy Officer) Grant / award / vesting 4,987 $0.00 $0 Form 4
2026-02-12 Kieffer Tara Lynn Officer (Chief Product Strategy Officer) Grant / award / vesting 1,575 $0.00 $0 Form 4
2026-02-12 Luu Brendan Officer (Chief Business Officer) Shares withheld for taxes / exercise cost 3,257 $14.25 $46.4K Form 4
2026-02-12 Luu Brendan Officer (Chief Business Officer) Grant / award / vesting 4,987 $0.00 $0 Form 4
2026-02-12 Luu Brendan Officer (Chief Business Officer) Grant / award / vesting 1,575 $0.00 $0 Form 4
2026-02-12 Kowalsky Matthew Paul Officer (Chief Legal Officer) Shares withheld for taxes / exercise cost 1,902 $14.25 $27.1K Form 4
2026-02-12 Kowalsky Matthew Paul Officer (Chief Legal Officer) Grant / award / vesting 4,175 $0.00 $0 Form 4
2026-02-12 Kowalsky Matthew Paul Officer (Chief Legal Officer) Grant / award / vesting 1,318 $0.00 $0 Form 4

Ask the chat about ENTA's insider activity →

Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.

Source: SEC EDGAR Form 3/4/5. See the full company profile: ENANTA PHARMACEUTICALS INC (ENTA).

Last updated 2026-03-11 (most recent filing date).

Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.